Certain statements contained in the blog entries, including, but not limited to, statements relating to the performance of Complete Genomics’ (Complete) technologies, such as future sequencing yields, accuracy and costs; the rates of adoption of complete human genome sequencing; the usefulness of the genomic data Complete provides to help identify possible genetic mutations and markers for diseases with a genetic basis; and future medical and clinical uses of complete human genome data are forward-looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward-looking statements are based on Complete’s current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the ability of scientists to successfully analyze the genomic data Complete provides; Complete’s ability to reduce the average cost of its sequencing service; the timing and extent of reductions in the price of Complete’s genomic sequencing service; and the ability of researchers to convert genomic data into medically valuable information. More information on potential risks and uncertainties is included in Complete Genomics’ Securities and Exchange Commission (SEC) filings and reports, including the risks identified under the section captioned “Risk Factors” in its Annual Reports on Form 10-K and other periodic reports filed with the SEC. The blog entries speak as of the date of such entry. Complete disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.
Dr. Clifford Reid
Chairman, President and CEO
Dr. Reid is a successful, serial entrepreneur. He enjoys commercializing disruptive computing and life sciences technologies.
Dr. Rade Drmanac
Chief Scientific Officer
Dr. Drmanac is a genome sequencing pioneer; his inventions include massively parallel DNA sequencing by hybridization and combinatorial probe ligation. As a group leader at the Argonne National Labs, he was part of the Human Genome Project. In 1993, he cofounded Hyseq, one of the first genomic companies.